Life Diagnostics, Inc. adds three new human cancer research assays to its extensive lineup of SPARCL assays. The assays were developed for CYFRA 21-1 (CYFR-SP-20), CA 19-9 (CA19-SP-20) and CA 72-4 (CA72-SP-20).
All three kits are for research use only.
- CYFRA 21-1 is a fragment of cytokeratin 19 produced by proteolysis in malignant tissues, and is used as a serum biomarker for some types of cancer.
- CA 19-9 is a carbohydrate antigen found on the MUC1 protein that is expressed and shed from some tumor cells. Increased serum levels of CA 19-9 may be associated with pancreatic and gastrointestinal cancer.
- CA 72-4 is a glycoprotein that is expressed on the surface of cancer cells. Increased levels of CA 72-4 are found in the serum of some cancer patients.
In addition to fully developed and tested SPARCL assay kits, Life Diagnostics provides HRP and acridan conjugation services for the development of new SPARCL assays. Please visit the Life Diagnostics SPARCL Assay web page for more information
